Abstract
Comment on Winter et al, page
Correlative data evaluating BCL6 protein expression and outcome in the US inter-group phase 3 randomized study of R-CHOP versus CHOP demonstrate that CHOP chemotherapy without rituximab is ineffective in BCL6-negative DLBCL.
